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Abstract
MYBBP1A is a predominantly nucleolar transcriptional regulator involved in rDNA synthesis and p53 activation via
acetylation. However little further information is available as to its function. Here we report that MYBBP1A is
developmentally essential in the mouse prior to blastocyst formation. In cell culture, down-regulation of MYBBP1A
decreases the growth rate of wild type mouse embryonic stem cells, mouse embryo fibroblasts (MEFs) and of human HeLa
cells, where it also promotes apoptosis. HeLa cells either arrest at G2/M or undergo delayed and anomalous mitosis. At
mitosis, MYBBP1A is localized to a parachromosomal region and gene-expression profiling shows that its down-regulation
affects genes controlling chromosomal segregation and cell cycle. However, MYBBP1A down-regulation increases the
growth rate of the immortalized NIH3T3 cells. Such Mybbp1a down-regulated NIH3T3 cells are more susceptible to Ras-
induced transformation and cause more potent Ras-driven tumors. We conclude that MYBBP1A is an essential gene with
novel roles at the pre-mitotic level and potential tumor suppressor activity.
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Introduction
The 160-kDa Myb-binding protein 1a (MYBBP1A, also
referred to as p160) is a nucleolar protein whose function is
mostly unknown. Although predominantly localized in the
nucleolus, MYBBP1A is found also in the nucleoplasm [1]; indeed
it contains nuclear and nucleolar localization sequences as well as
export signals in the C-terminus [2,3]. Unlike full length
MYBBP1A/p160, its shorter N-terminal 140 KDa and 67 kDa
forms are mainly localized in the nucleoplasm due to processing of
the nucleolar localization signal at the C-terminus. MYBBP1A
processing is regulated by stress signals affecting ribosomal
biosynthesis, which induce its translocation from the nucleolus to
the nucleoplasm [3,4].
The ubiquitously expressed MYBBP1A was originally identified
as an interactor of the c-Myb oncoprotein with homology to the
fifth essential DNA polymerase of S. cerevisiae [1,5]. MYBBP1A
binds to and inhibits several transcription factors, such as the
PPARc co-activator 1a (PGC-1a) [6]. In addition, it binds the
RelA/p65 subunit of NF-kB and suppresses its trans-activating
capacity by competing with p300 [7]. MYBBP1A also binds the
developmentally essential Prep1 homeodomain transcription
factor and inhibits its activity by competing with its DNA-binding
partner Pbx1 [4]. MYBBP1A is also a component of the Ret–CoR
co-repressor complex [8]. In contrast to these inhibitory activities,
MYBBP1A binds to and stimulates the aryl hydrocarbon receptor
(AhR) [9]. Finally, MYBBP1A is stabilized by Prep1 at least in the
skeletal muscle, and its decrease in the Prep1-hypomorphic mice is
responsible for the hyper-activation of PGC-1a and increased
insulin sensitivity [10].
MYBBP1A is also required for the acetylation and subsequent
stabilization of p53 since it prevents Mdm2-dependent degrada-
tion of p53 [11]. Inhibition of p53 acetylation blocks Cdkn1a (p21)
transcription and induces cell cycle arrest and apoptosis [12,13].
Finally, MYBBP1A has also been linked to mitosis, since it is a
substrate of Aurora-B kinase [14].
These multiple and diverse functions of MYBBP1A suggest that
this protein plays an important role in essential biological functions
such as cell division, cell proliferation and apoptosis. However
nothing is known of its importance relative to other well-known
regulators of these pathways, nor about its physiological function
during development. Indeed, at least some functional interactors of
MYBBP1A, such as p53, are not essential during development. It
is clear, therefore that in vivo data are essential to fully evaluate the
function of MYBBP1A.
In this paper we report that MYBBP1A is essential for early
mouse development prior to blastocyst formation. We also report
that MYBBP1A down-regulation induces apoptosis and mitotic
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anomalies in mouse embryonic stem cells, embryonic fibroblasts
and human HeLa cells, where it alters the expression of key cell
cycle regulators. Moreover, Mybbp1a may act as a tumor
suppressor, as its down-regulation facilitates the transformation
of NIH3T3 cells by the HRas oncogene.
Materials and Methods
Generation of Mybbp1a-targeted mice
The mice were housed in the University of Adelaide Medical
School Animal House and all mouse work was covered by ethics
approval from both the Institute of Medical and Veterinary
Science and the University of Adelaide animal ethics committees.
This project was covered by University of Adelaide Animal Ethics
Committee approvals M6098 and M5201 and IMVS Animal
Ethics Committee project no. 69/98.
The Mybbp1a targeting vector was constructed from sequences
subcloned from an E14TG2a ES cell genomic library. A 3.8 kb 59
genomic fragment containing the promoter region approximately
450 bp upstream from the initiation ATG was generated by PCR
amplification using oligos (KO1: 59-ATAAGAATGCGGCC-
GCTCTGTCCATTGTTGTTCTGC-39; KO2:59-GCTCTAG-
AATGTAGGGAGCAGAGGGAGCC-39) incorporating NotI
and XbaI sites at the 59 and 39 ends respectively. A 6.0 kb XbaI/
HindIII 39 genomic fragment encompassing part of exon 14, exons
15–26 and 39 flanking sequences was cloned downstream of the 59
fragment. The 1.8 kb pgkNEO expression cassette [15] was inserted
into the XbaI site between the two Mybbp1a genomic fragments in
the opposite transcriptional orientation to the Mybbp1a gene
(Suppl. Figure S1). The Mybbp1a targeting vector was electropo-
rated into theW9.5 ES cell line and selected with G418 as described
[16]. Homologous recombinants were identified by Southern
analysis of XbaI-digested DNA isolated from individual clones.
Southern blots were hybridized with the 59 genomic DNA probe
(Suppl. Figure S1), a 950 bp fragment located 60 bp upstream of
the 59 end of the targeted region. This probe was generated by PCR
amplification using the oligonucleotides: 59-CTTGGGTCT-
TCTTGGGGTTCC-39; 59-GCCAGCATGGCAGGCTTGG-39.
The targeted deletion was confirmed by further analysis of Southern
analysis of selected clones with the 39 genomic DNA probe (Suppl.
Figure S1 and below). Targeted clones were injected into C57BL/
6 blastocysts. Germline transmission was seen for a single clone and
chimeric offspring were bred to C57BL/6 mice to derive
heterozygous MYBBP1A+/2 mice.
Analysis of Mybbp1a2/+6Mybbp1a2/+ crosses
Chimeric mice and their heterozygous progeny were back-
crossed for at least six generations onto a C57BL/6 background.
Mouse genotyping was performed on tail DNA of weaned mice
and E11.5 embryos prepared using DNeasy kits (Qiagen),
Southern blot analysis of XbaI-digested DNA and probing with
the 59 probe as described above and shown in Suppl. Figure S1
B, C. Mouse embryos were genotyped by PCR using oligonucle-
otides KO3 and KO4 to detect the wild type allele (488 bp
product) and KO3 and KO5 to detect the targeted allele (570 bp
product) as shown in Suppl. Figure S1 D. (KO3: 59-
AAGGCTCCCTCTGCTCCCTAC-39; KO4: 59-GGCTCTT-
CATCTCCGCCATGC-39; KO5: 59-GCGCATCGCCTTCTA-
TCGCC-39). DNA from E9.5, E6.5 embryos and from blastocyst
outgrowths was prepared by boiling at 100uC for 8–10 min in
water:PBS (1:1). Blastocysts were cultured in DMEM containing
10% FCS for 4–6 days and outgrowth material was collected for
PCR analysis as above.
Cell culture and treatment
Wild-type ES cells were derived from E2.5–3.5 C57Bl/6
embryos using standard procedures [17]. Cells were cultured in
LIF-containing medium (DMEM+GlutaMAXTM-I, Gibco) com-
plemented with 15% Fetal Calf Serum, 0.1 mM nonessential
aminoacids, 1 mM sodium pyruvate and 0.1 mM b-Mercapto-
ethanol, on 0.2% gelatin-coated dishes. After Mybbp1a -shRNA or
empty vector lentiviral infection and puromycin selection (1 mg/
mL), 1.256105 cells per well were plated in 6-well plates and
cultured. Cells were harvested and counted in triplicate on days 1,
2 and 3.
MEFs were derived from wt C57BL/6 embryos using standard
procedure.
NIH3T3, MEFs, HeLa and Phoenix cells were grown at 37uC,
5% CO2 in Dulbecco’s modified Eagle’s medium (DMEM, Gibco)
supplemented with 10% heat-inactivated fetal bovine serum (FBS,
Euroclone), 0.2 mg/ml streptomycin (Gibco), 20 U/ml penicillin
(Gibco), 2 mM glutamine (Gibco) and 1 mM sodium pyruvate
(Gibco). HEK 293T were grown in Iscove’s Modified Dulbecco’s
medium (IMDM, Cambrex) supplemented with 10% FBS,
0.2 mg/ml streptomycin, 20 U/ml penicillin and 2 mM gluta-
mine.
To block cells at the G1/S transition, a double-Thymidine
block was used. Cells (NIH 3T3 or HeLa) were treated with 2 mM
Thymidine (Sigma) for 18 hours (first block), followed by a release
of 9 hours and a second pulse with 2 mM Thymidine for 17 h
(second block).
To transiently silence MYBBP1A in HeLa cells, 26105 cells/well
were plated in triplicate in 6-well plates for 24 hours, transfected
using lipofectamine (Invitrogen) with 40 nM siRNA or control
oligonucleotides (High-GC, Medium-GC, Invitrogen), following
the manufacturer protocol. The sequences of the siRNAs are the
following:
siRNA1 (CCAGGCTGGTGAATGTGCTGAAGAT, 52%
GC);
siRNA2 (CCCTGCAGCTAATTCTGGATGTGCT, 52%
GC);
siRNA3 (GAGGTCCTCAAAGCCGACTTGAATA, 48%
GC).
For retroviral infection and selection of stable clones, Phoenix
ecotropic packaging cells [18] were transfected with 10 mg of
retroviral plasmid using the calcium phosphate protocol [19] and
incubated overnight. Two days post- transfection NIH 3T3 cells
were infected with the filtered viral supernatant and supplemented
with 8 mg/ml of Polybrene (Sigma) for 4 h at 37uC. Antibiotics
were added 24 h post infection for the selection: Geneticin for
pRufNeo-p160-Flag (1 mg/ml, Gibco) [20] and Hygromycin for
pBabe-Myc and –RasVal12 (200 mg/ml, Invitrogen).
For lentiviral infection and selection of stable clones, HEK
293T cells were transfected with 3.5 mg ENV plasmid (VSV-G),
5 mg packaging plasmid (pMDLg/p RRE), 2.5 mg of pRSV-REV
and 15 mg of the target plasmid (pLKO.1-puro, containing one of
the five different shRNA target sequences, Sigma) following a
calcium phosphate transfection protocol. The day after transfec-
tion the medium was replaced by fresh medium supplemented
with 1 mM Sodium Butyrate (Sigma). After 30 h, the viral
supernatant was collected and used to infect NIH 3T3 cells. The
day after the infection 2 mg/ml Puromycin was added to the
medium for selection. The shRNA target sequences are the
following:
shRNA1 (CCGGCCTGCCCTAGAGACTCCTATTCTC-
GAGAATAGGAGTCTCTAGGGCA);
shRNA2 (CCGGCCTGATGAAGTCCGTGCAATTCTC-
GAGAATTGCACGGACTTCATCA);
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shRNA3 (CCGGCCGGAGTGTATTTGGTCATATCTC-
GAGATATGACCAAATACACTC);
shRNA4 (CCGGCCCAATGATTCGGAGATGAAACTC-
GAGTTTCATCTCCGAATCATTG);
shRNA5 (CCGGCCAAGCGTAACAGCTCACTTACTC-
GAGTAAGTGAGCTGTTACGCTT).
As controls, commercial High-GC and Medium-GC content
shRNAs (Invitrogen) were used as suggested by the manufacturer.
Proliferation assay
Measurement of HeLa cell proliferation was performed by
plating 26105 cells/well in a 6-well plate and transfecting them
with lipofectamine the day after. At 24, 48 and 72 h after
transfection the cells were detached and counted with a cell
counter (Coulter Z1, Coulter Diagnostics).
Crystal Violet assay was performed plating 3,000 cells/well in a
12-well plate and fixing the cells at the following time points: T0
(8 h after plating) and 2, 4, 6, 8, 10 days after. Cells were washed
in PBS, fixed with 11% glutaraldehyde (Sigma) for 15 min. at RT,
washed again in PBS and allowed to dry at RT. Cells were stained
with Crystal Violet solution (0,1% crystal violet -Sigma- in 20%
Methanol, 80% dH2O) for 20 min. at RT. Cells were washed with
dH2O and dried at RT. Stained and dried cells were solubilized
with a solution of 10% Acetic Acid for 10 min. at RT and
analyzed with a Microplate Reader 680 (Bio-Rad) at 570 nm.
Long term proliferation experiments were performed by plating
300000 cells in 6-well plates. After 3 days, cells were counted with
a cell counter (Coulter Z1, Coulter Diagnostics) and plated again
at 300000 cells per well and counted again the third day. The
procedure was repeated 5 times.
Immunoblot analysis
Cells were washed with PBS 16and scraped with RIPA buffer
(100 ml for 10 cm dish; buffer composition: 5 mM Tris-HCl pH 8,
150 mM NaCl, 0.1%, SDS 1% NP-40, 0.5%, Na-deoxycholate,
16Complete Protease Inhibitor, EDTA free, Roche). Cells were
incubated on ice for 30 min and after centrifugation at
14,000 rpm for 15 min at 4uC, protein concentration was detected
with the Bradford reagent (Bio-Rad Protein Assay, Bio-Rad) and
measurement at 595 nm with Ultraspectrophotometer 2100pro.
Protein extracts were resuspended in Laemmli buffer [30], heated
for 5 minutes at 95uC, loaded on a 10% gradient sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and im-
munoblotted with the indicated antibodies.
ES cell immunoblotting analysis was performed with anti-Oct-
3/4 (C-10) (1:500, Santa Cruz), anti-Cleaved Caspase-3 (Asp175)
(1:1000, Cell Signalling), anti p160, and anti-Vinculin (1:5000,
Sigma).
Immunocytochemical analysis and confocal microscopy
Cells were grown on sterile 13 mm glass coverslips (VWR
international) for at least 24 h. Cells were washed with PBS and
fixed (3% paraformaldehyde; 2% sucrose in 16PBS) for 10 min at
RT. After washing with PBS, cells were permeabilized with 0.2%
PBS-Triton X-100 for 5 min at RT, washed with PBS and blocked
with 16 PBS-1% BSA for 30 min at RT. Coverslips were
incubated with the indicated antibodies in blocking solution for
30 min at 37uC. Cells were washed with PBS and incubated with
the secondary antibodies (Alexa-488 and Alexa-546 conjugated
anti-mouse or anti-rabbit immunoglobulin) and incubated for
30 min at RT protected from light. Cells were washed again with
PBS and incubated with 496-diamidino-2-phenylindole dihydro-
chloride (DAPI) nuclear staining (Fluka) for 3 min at RT or
Hoechst 33258 (same conditions, Sigma). Cells were then washed
with PBS and coverslips mounted with Fluorescent Mounting
Medium (Dako Cytomation). Images were obtained with a Leica
DMIRE2 (Confocal System Leica TCS SP2) with a 636objective.
Incubations with matched mouse isotype IgGs, irrelevant rabbit
IgGs or secondary antibodies were always negative.
ImmunoFISH
After the washing step following the incubation with the
secondary antibodies, cells were fixed again in 4% paraformalde-
hyde, 0.1% Triton X-100 at 4uC for 30 minutes. Cells were then
incubated for 30 min at RT with 100 mM Glycine (VWR) and
washed once with PBS. FISH was performed with Telomere PNA
FISH kit/Cy3 (DAKO) following the manufacturer instructions;
PNA probe was labeled with Cy3.
Time-Lapse microscopy
Cells were plated in a 6-well plate (26105 cells/well in
triplicate), transfected as described above with siRNA or High-
GC control and blocked at the G1/S transition using a double
thymidine block. Starting 8 h after the release from the block and
up to 24 hours later, the cells were analyzed with Time Lapse
Microscope (OKO VISION). Images were taken in 4 different
fields for each sample every 5 min with a 56 objective and
analyzed with Image J software.
Flow Cytometry analysis
For 59ethynyl-29-deoxyuridine (EdU)/7-amino-actinomycin D
(7-AAD) double staining, cells were grown and pulsed before the
assay with 10 mM EdU for 1 hour, harvested and processed with
Click-iT EdU Flow Cytometry Assay kit (Invitrogen) following the
manufacturer protocol. Anti-EdU-Fluorescein-isothycyanate
(FITC) was used to stain EdU positive cells and 7-AAD was used
to stain DNA. Cells were analyzed with FACS CANTO or FACS
Calibur (BD Immunocytometry). Results were displayed as
bivariate distribution of EdU content versus DNA content. The
percent of cells in the S-phase was calculated by gating EdU
positive cells using FCS Express V3 (De Novo Software) or
CellQuest program (BD).
For Annexin V staining, cells were harvested, washed with PBS
16and the dead and apoptotic cells were detected by Annexin V
Phycoerythrin (PE)/7-AAD staining using PE Annexin V Apop-
tosis Detection kit I (BD Pharmingen), following the manufactur-
er’s instructions. Cells were analyzed with FACS CANTO or
Calibur (BD) and results were displayed as bivariate distribution of
Annexin V positive cells versus 7-AAD positive cells. The
percentage of early apoptotic cells was calculated by gating
Annexin V positive cells using FCS Express V3 or CellQuest
programs.
Gene expression profiling
Real-Time PCR. Total RNA was extracted (RNAeasy
minikit, QIAGEN) and quantified by spectrophotometry (Nano-
drop, Thermo Scientific). Total RNA (5 mg) was reverse-
transcribed using a SuperScript First-Strand kit with random
primers (Invitrogen) according to the manufacturer’s instructions.
For quantitative Real-Time PCR, 20 ng of the reverse-transcribed
RNA was amplified with a Light-Cycler 480 (Roche) using a
Universal Probe Library Assay (Roche) and following the
manufacturer instructions. The PCR conditions were as follow:
pre-incubation at 95uC for 5 minutes, 50 cycles of amplification
(denaturation at 95uC for 10 s, annealing at 58uC for 15 s and
extension at 72uC for 1 s), cooling at 40uC for 10 s. The amount of
the different mRNAs was normalized to GAPDH mRNA. The
MYBBP1A, Cell Cycle and Cancer
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sequences of the primers used with the relative probes are the
following: MYBBP1A (probe 10, L: AGCACCTTCTGCTC-
CTCGT, R: ATGCAGGTCTGGATGTCACC); CDKN1A
(probe 32, L: TCACTGTCTTGTACCCTTGTGC, R: GGCG-
TTTGGAGTGGTAGAAA); NFKB2 (probe 10, L: CACAT-
GGGTGGAGGCTCT, R: ACTGGTAGGGGCTGTAGGC);
GADD45B (probe 10, L: CATTGTCTCCTGGTCACGAA, R:
TAGGGGACCCACTGGTTGT); JUN (probe 19, L: CCAAAG-
GATAGTGCGATGTTT, R: CTGTCCCTCTCCACTGCA-
AC); TOP2B (probe 66, L: TCCAAGAGATTCTTTGCTTAG-
GA, R: CATCCTCTTCTTCTGAGAAATCAAA; GAPDH
(probe 60, L: AGCCACATCGCTCAGACAC, R: GCCCAA-
TACGACCAAATCC). The following genes were analysed with
Applied Biosystems probe sets: CKS1b (probe Hs01029137_g1);
SFN (probes Hs00602835_s1 Hs00968567_s1); TOP2A (probe
Hs00172214_m1; WEE1 (probe Hs00268721_m1); BRCA1
(probe Hs00173233_m1); CDK7 (probe Hs00361486_m1).
RNAs from three technical replicates of HeLa cells transfected
with High-GC control or siRNA1, were analyzed with Affimetrix
Human Gene 1.0 ST chip (Affimetrix). Biotin-labelled cDNA targets
were synthesized starting from 100 ng of total RNA. Double stranded
cDNA synthesis and related cRNAwas obtained with GeneChipWT
cDNA Synthesis and Amplification Kit (Ambion). With the same kit
the cDNA sense strand was synthesized, then fragmented and
labelled with GeneChip WT Teminal Labeling Kit (Ambion). DNA
fragmentation was performed with a combination of uracil DNA
glycosylase (UDG) and apurinic/apyrimidinic endonuclease 1 (APE
1), while labeling was completed using terminal deoxynucleotidyl
transferase (TdT) in the presence of GeneChipH DNA Labeling
Reagent. All steps of the labelling protocol were performed as
suggested by Affymetrix (http://www.affymetrix.com/support/
technical/manual/expression_manual.affx). The size and the accu-
racy of quantification of targets were checked by agarose gel
electrophoresis of 2 ml aliquots of each sample after fragmentation.
External controls (spikes) were used; each eukaryotic GeneChipH
probe array contains probe sets for several B. subtilis genes that are
absent in the samples analyzed (lys, phe, thr, and dap). This Poly-A
RNA Control Kit contains in vitro synthesized, polyadenylated
transcripts for these B. subtilis genes that are pre-mixed at staggered
concentrations to assess the overall success of the assay. Samples were
then hybridized as indicated by Affymetrix. A single GeneChip
Human Gene 1.0 ST was then hybridized with each biotin-labelled
sense target. Hybridizations were performed for 16 h at 45uC in a
rotisserie oven. GeneChip cartridges were washed and stained with
GeneChip Hybridization, Wash and Stain Kit in the Affymetrix
fluidics station following the FS450_0007 standard protocol. Images
were scanned using an Affymetrix GeneChip Scanner3000 7G with
default parameters. The resulting images were analysed using
GeneChip Operating Software v1.2 (GCOS1.2). Raw data were
first normalized using RMAmethod [21–23]. In order to evaluate the
variability between samples, Principal Component Analysis (PCA)
was performed. After this analysis an ANOVA test and a False
Discovery Rate (FDR) [24,25] to exclude false positives) was applied
and the resulting gene-list was refined with a p value#0.05 and a fold
change$1.75. Gene ontology analyses of the differentially expressed
genes were performed with the DAVID 6.7 functional annotation
tool (Database for Annotation, Visualization and Integration
Discovery – NIH, http://david.abcc.ncifcrf.gov/home.jsp) according
to [26].
Colony forming assay
Cells were resuspended in DMEM with 0.3% agar at a
concentration of 5,000 cells/well and plated over a 0.6% agar
layer in a 6-well plate. The experiment was performed in triplicate
and plates were incubated at 37uC in a humidified incubator for
two weeks. Colony detection was performed by staining cells with
3-(4,5-dimethylthiazol-2-ye)-2,5-diphenyltetrazolium bromide
(MTT, 1:10 in PBS 16) for at least 4 h. After staining, the plate
was scanned and the image obtained was analyzed with Image J
Software.
Tumorigenesis in nude mice
NIH 3T3 cells were infected with either an lentivirus empty
vector (NT) or a vector expressing specific Mybbp1a shRNA (Sh3,
see above) and selected with puromycin (4 mg/mL). After
selection, stable puromycin-resistant pools were subsequently
infected with pBABE-RasV12 or empty pBABE vector (as
indicated), selected with 50 mg/mL hygromycin and 46106 cells
for each condition were injected in nude mice (6 mice per group).
After the injection, mice were monitored daily for 18 days and
tumor volume measured every 2 days.
Antibodies
The following antibodies were used: mono- and polyclonal
antibodies against Flag (Sigma-Aldrich, St. Louis, MO, USA);
polyclonal antibody against p160C (Zymed laboratories Inc.,
South San Francisco, CA, USA); mouse monoclonal antibody
against Prep1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA);
mouse monoclonal antibody against Tubulin (Sigma); rabbit
polyclonal antibody against Phospho Histone H3 (Millipore
Upstate Biotechnology, NY, USA); human monoclonal antibody
against CREST (homemade); mouse monoclonal antibody against
Nucleolin (Santa Cruz Biotecnology); mouse monoclonal antibody
against Nucleophosmin (Invitrogen, Camarillo CA, USA); rabbit
polyclonal antibody against active Caspase3 and mouse monoclo-
nal antibody against Caspase 9 (MBL, Woburn, MA, USA).
Results
Deletion of Mybbp1a in the mouse leads to embryonic
death prior to blastocyst formation
The experimental approach used to knock out the mouse
Mybbp1a gene is shown in Supplementary Figure S1 (see also
Materials and Methods). The Mybbp1a targeting vector comprised
3.5 kb of 59 genomic flanking sequence and 6.0 kb of genomic
sequence encompassing part of exon 14, exons 15–26 and 39
flanking sequences. Recombination resulted in the deletion of the
59 half of the coding region of the gene (5.5 kb) including the
ATG, exons 1 to 13 and a half of exon 14 (Suppl. Figure S1A).
Healthy and fertile heterozygous Mybbp1a+/2 mice were obtained.
However heterozygous crosses yielded no homozygous knockout
mice, indicating that Mybbp1a is essential for mouse development
(Table 1). Analysis of embryos at various times of development
yielded no homozygous Mybbp1a2/2 embryos at E11.5 (p,0.05),
E9.5 (p,0.05) nor at E6.5 (p,0.05). Blastocysts were then isolated
from a Mybbp1a+/2 heterozygous cross, grown in culture for
several days and genotyped. No Mybbp1a 2/2 blastocysts were
detected (Table 1). These results strongly indicate that Mybbp1a is
essential during the very early stages of embryonic development
before blastocyst formation.
MYBBP1A is required for proper cell growth
To investigate the molecular determinants of this phenotype, we
down-regulated Mybbp1a in wild type C57BL6 ES cells using
shRNA technology (shRNA3, see Methods; see also below for the
effect of other MYBBP1A shRNAs). Within 72 h of transduction,
MYBBP1A shRNA3 retrovirus reduced Mybbp1a protein expres-
sion by 82% with respect to non-targeting shRNA (Figure 1B).
MYBBP1A, Cell Cycle and Cancer
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After 72 hrs the number of ES cells was about five fold less than in
the controls while the doubling time doubled (Figure 1A).
Concomitantly, the level of active caspase-3 increased by 3.65 fold
(Figure 1C–D), consistent with the decrease in cell number.
This drastic and sudden effect may be the cause of the early
embryonic lethal phenotype. The survival of a (small) fraction of
Mybbp1a -down-regulated cells (Figure 1A) is probably due to the
incomplete down-regulation.
To test the generality of this effect, we have down-regulated
Mybbp1a in other mouse cells (MEFs and NIH3T3) and in human
HeLa cells. Primary MEFs (only two passages in culture) down-
regulated for Mybbp1a showed a rapid entry into senescence
compared with cells treated with non-targeting vector (NT) in a
long term proliferation protocol (Figure 2A,B). In human HeLa
cancer cells, MYBBP1A was efficiently down-regulated by three
tested siRNAs, in particular siRNA-1 and -3 (see Figure 2F and
Methods); these achieved about 80% down-regulation within 48 h
of transfection. Figure 2E shows that cells transfected with any of
the three siRNAs grew appreciably slower than controls
(commercial oligonucleotides of High or Medium GC content,
see Methods).
Surprisingly, a different result was obtained using NIH3T3 cells,
which are immortalized cells that can be transformed by a single
oncogene. In this case, down-regulation of Mybbp1a caused an
increased growth rate as measured by the crystal violet assay; we
noted however, that knock-down was less efficient in these cells
(Figure 2C, D).
Overall, these results show that both in most of the cell types
tested, MYBBP1A is required for normal rates of cell proliferation.
Table 1. Timed pregnancy analysis of heterozygous
MYBBP1A+/2 crosses.
Time of analysis N
N
+/+
N
+/2
N
2/2
N
NP p-value
Birth 61 11 50 0 0 ,0.05
E11.5 18 5 13 0 0 ,0.05
E9.5 22 7 15 0 0 ,0.05
E6.5 28 10 15 0 3 ,0.05
Blastocyst 30 8 20 0 2 ,0.05
N= Total number.
NP =No PCR product.
doi:10.1371/journal.pone.0039723.t001
Figure 1. Specific down-regulation of Mybbp1a in wild type ES cells blocks proliferation and induces activation of caspase-3. (A) ES
cells were infected with the Mybbp1a-specific shRNA3 or with an empty non-target (NT) lentivirus vector (see Materials and Methods), and the
proliferation rate was measured starting two days after infection (0 h) every 24 h, using a cell counter. (B). At the end of the experiment (72 h) the
cells were lysed and the extract immunoblotted with Mybbp1a-specific antibodies (anti-p160C) using Tubulin as loading control. (C, D). The extracts
were also immunoblotted against Oct4 (for specificity of the down-regulation) and cleaved-Caspase 3 for apoptosis using Vinculin as loading control.
doi:10.1371/journal.pone.0039723.g001
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The different effect observed in NIH3T3 cells upon Mybbp1a
knock-down (growth acceleration rather than inhibition) was
surprising and will be discussed further below.
MYBBP1A knock-down in HeLa cells induces apoptosis,
blocks surviving cells in the G2/M phase and causes
mitotic aberrations
We next investigated the basis for cell growth inhibition induced
by MYBBP1A knock-down in HeLa cells. First, time-lapse
experiments showed major mitotic abnormalities in MYBBP1A-
down regulated HeLa cells. In most control cells the time required
for mitosis was about 70 minutes but increased to an average of 92
after MYBBP1A-down regulation (Figure 3A). Examples are
shown in Suppl. Fig. S5. In addition, 20% of the siRNA
transfected cells did not divide at all (vs. 10% in Control) while
about 40% died (4% in Control) (Fig. 3B).
Consistent with this, we found that MYBBP1A-down regulated
HeLa cells undergo a specific block of the cell cycle at G2/M.
Flow cytometry for EdU and 7AAD (Figure 4A), in MYBBP1A-
down-regulated HeLa cells, showed a 3-fold increase in the
number of cells in G2/M (14 v. 5%) and a decrease in the number
of cells in S phase, suggesting that the growth of the cells is delayed
due to a block prior to cytokinesis. Interestingly (see also below)
there may be a minor effect at the G1/S checkpoint (see
Discussion). Upon direct microscopic observation, MYBBP1A-
depleted cells contained in fact a much higher number of mitotic
figures than controls (7% v. 4%, Figure 4B) but these were largely
aberrant (Figure 4D); in particular, we observed altered
metaphase plates and cytodieresis and multi-polar spindles
(Suppl. Fig. S6B). No such aberrations were observed in the
control cells (Suppl. Fig. S6A). These data suggest that
MYBBP1A-down regulation causes a block/delay of cells in S/
G2/M and that those cells that reached mitosis acquired major
abnormalities. Finally, the number of cells in prophase increased
at the expense of those in anaphase (Figure 4C).
MYBBP1A-down regulation in HeLa cells also induces apopto-
sis. Indeed at 48 and 72 hrs, flow cytometry with Annexin-V vs.
7AAD showed about 10% and 15% early apoptotic cells (Annexin
V-positive, 7AAD-negative), respectively, upon siRNA-transfec-
tion, compared to control transfection (about 6%) (Figure 5A).
This was confirmed by immunoblotting with anti-active caspase 3
and anti caspase-9 antibodies (Figure 5B). In fact, the percent of
Annexin-positive/7AAD-positive cells also increased upon
Figure 3. MYBBP1A-depletion slows the growth of HeLa cells. (A) Measure of the length of mitosis with Time-Lapse video imaging of HeLa
cells transfected with High-GC or siRNA1 for 48 h after synchronization with a double thymidine block. The numbers below the histograms identify
groups of cells with different mitosis length. Cells analyzed= 40 per group. (B) Percentage of dividing, not dividing or dead cells during the period
analyzed by Time-Lapse microscopy; individual cells analyzed= 60.
doi:10.1371/journal.pone.0039723.g003
Figure 2. Down-regulation of Mybbp1a in primary wild type MEFs and in NIH3T3 cells has opposite effects on cell proliferation. (A)
Down regulation of Mybbp1a in MEFs with the specific lentiviral vector shRNA3 induces early senescence, as opposed to a non-target empty (NT)
vector. (B) Immunoblot of the cells of panel A showing down regulation of MYBBP1A (p160), using tubulin as control. (C) Growth rate determination
(crystal violet assay, see Methods) in Mybbp1a down-regulated NIH3T3 cells with lentiviral vectors expressing specific Sh1RNA or Sh3RNA, as opposed
with control empty Non Target vector (NT). Crystal violet assays were performed over 10 days counting the cells in triplicate every 2 days. The p-value
of the difference between Sh3 and NT-treated cells was #0.001 (t test). (D) Immunoblot of the cells of panel C. (E) Growth rate determination of
MYBBP1A down-regulated HeLa cells by specific siRNAs (see Methods). Ctl: untreated cells. Lipo: transfection control with lipofectamine only. High GC
and Medium GC: two control oligonucleotides (indicated by the siRNAs manufacturer) of high and, respectively, medium GC content. siRNA1, siRNA2
and siRNA3: specific MYBBP1A siRNAs (see Methods for sequences). (F) Immunoblots of the cells of panel B upon culturing for 24, 48, 72 and 96 h
after transfection.
doi:10.1371/journal.pone.0039723.g002
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MYBBP1A down-regulation (50+/210% at 48 h and 80+/230%
at 72 h) (data not shown). This suggests an even greater effect on
cell death.
At mitosis, MYBBP1A assumes a para-chromosomal
localization
The growth inhibition, extension of mitosis and G2/M block
upon down-regulation of MYBBP1A all point to a possible
involvement of MYBBP1A in mitosis. Since nucleoli are disrupted
at mitosis we examined the localization of the nucleolar protein
MYBBP1A in various phases of mitosis. Fig. 6B, C show that in
NIH3T3 cells expressing Mybbp1a-flag, Mybbp1a co-localized
with Nucleolin and Nucleophosmin (NPM) in nucleoli (see below).
However, in metaphase and anaphase Mybbp1a was found in the
nucleoplasm, particularly concentrated around the chromosomal
plate. Nucleolin and NPM also exit the nucleolus at mitosis and
co-localized with MYBBP1A at interphase; however, at meta-
phase, NPM (but not nucleolin) and Mybbp1a largely colocalized
in the para-chromosomal regions. Suppl. Figure S2B shows that
the distribution of Mybbp1a is not due to overexpression, since the
same pattern is observed when endogenous Mybbp1a is examined
in non-overexpressing cells with an antibody recognizing only the
full-length protein.
At metaphase and anaphase, immunofluorescent staining (IF)
showed that Mybbp1a co-localized with phospho-histone H3
(Figure. 6A), a chromatin marker. No co-localization of
Mybbp1a was seen with inner kinetochore components (like
constitutive centromere proteins CENP-A, -B, and –C) as shown
by IF with anti-CREST antibodies, nor with telomeres, as shown
by Immuno-FISH with a PNA probe (Suppl. Fig. S3).
From these data we conclude that Mybbp1a translocates from
nucleoli to the nucleoplasm during mitosis, and in metaphase-
anaphase is found spread throughout para-chromosomal regions,
in apparent colocalization with a chromatin marker.
The same results were obtained with other cell lines, e.g. HeLa
cells (See Suppl. Figure S4) where MYBBP1A again assumes a
parachromosomal localization. Hence the differential effect of
Figure 4. MYBBP1A-depleted HeLa cells are blocked in S/G2. (A) Flow cytometry and cell cycle analysis of HeLa cells after EdU incorporation
using anti-EdU antibodies and 7-AAD. Flow cytometry histograms show cell cycle distribution and quantitation of HeLa cells transfected with High-GC
or siRNA1 oligonucleotides, at 72 h post-transfection. (B) Quantitation of mitotic figures in control (High GC) and siRNA1 transfected HeLa cells
performed with confocal microscope. (C) Quantitation of cells in the various phases of cell cycle in control (High GC) and siRNA1 transfected HeLa
cells by confocal microscope. (D) Measurement of the percentage of anomalous mitotic figures in control (High GC) and siRNA1 treated HeLa cells by
confocal microscope.
doi:10.1371/journal.pone.0039723.g004
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MYBBP1A down-regulation in HeLa v. NIH3T3 cells is not due
to a different mitotic localization.
MYBBP1A down-regulation affects the expression of cell
cycle and growth controlling genes
Gene expression profiling of control and siRNA down-regulated
HeLa cells (two biological duplicates) was carried out on an
Affymetrix Gene ST 1.0 Human platform. Of the 28829 genes
analyzed, 853 were differentially expressed (increased or decreased
more than two fold: (p,1024); 71.4% of the genes were down-
regulated and 28.6% up-regulated upon MYBBP1A silencing
(Table 2). Functional annotation clustering of the differentially
expressed genes with the DAVID software (http://david.abcc.
ncifcrf.gov/) shows that 49.8% of these genes fall into categories
involved in cell-cycle, mitosis, DNA-damage and stress response,
apoptosis, chromosome segregation and chromatin (Table 3).
Since our experiments suggested a growth-arrest at G2/M and
genes of this pathway were the most enriched cell cycle genes in
our data set (Table 4), we specifically validated this pathway by
real-time PCR measurement of a subset of these genes (Table 5).
In addition to the decrease of MYBBP1A itself, genes encoding
major cell cycle or DNA damage-related proteins, were affected:
CDKN1A, GADD45B and SFN were induced while TOP2A,
TOP2B, BRCA1, CDK7 and WEE1 were down-regulated. This is
in keeping with the above results and confirms that MYBBP1A
affects cell-cycle regulation. Indeed, pathway analysis (Ingenuity
Pathway Analysis, Ingenuity Systems) shows that in the G2/M
pathway 3 out of 5 of the CDC2/CYCLINB2 activating genes are
down-regulated (BRCA1, CDK7, WEE1) while 2 out of 3 of the
inactivating ones (CDKN1A and GADD45B) are overexpressed
(not shown). Importantly, among the validated genes, TOP2A,
TOP2B, GADD45A and CDKN1A are also connected to mitotic
dysfunction, in agreement with the data of Figure 4 and Suppl.
Figure 6.
Reduction of MYBBP1A enhances the oncogenic activity
of RasVal12
Since the down-regulation of MYBBP1A affected cell growth
and chromosomal stability, we considered whether it might also
affect the activity of oncogenes. We therefore tested the effect of
Mybbp1a down-regulation in the mouse NIH3T3 cell line which is
particularly suited to tumorigenesis studies, and in which
Mybbp1a down-regulation accelerated rather than inhibited cell
growth (Figure 2C). As shown above, vectors containing shRNA3
or shRNA1 down-regulated Mybbp1a on average by about 60%
(see Fig. 2D).
When co-infected with a HaRasVal12 retrovirus, NIH3T3 cells
formed a higher number of colonies in soft agar than controls
(Fig. 7A), suggesting that decreased Mybbp1a favors Ras
transformation. Therefore, we also tested whether MYBBP1A
down-regulation affected the tumorigenic activity of control and
Ras-transformed NIH-3T3 cells upon injection into nude mice. As
Figure 5.MYBBP1A down-regulation induces apoptosis. (A) HeLa cells were transiently transfected with siRNA1, 2 or 3, or with control High-GC
or Medium-GC oligonucleotides, or with Lipofectamine only, for 48 h. The figure shows the determination of early apoptotic cells by flow cytometry
(i.e. Annexin V positive and 7AAD-negative) (left panel, circled gate) 48 h post transfection. The histogram on the right shows the quantification in
the various samples at the different times after transfection. In untreated cells only 1% of the cells were in apoptosis. (B) Western-blot analysis of
HeLa cells transiently transfected for 48 h with CTL (untreated cells), LIPO (treated only with lipofectamine), HIGH GC (transfected with High-GC
control), siRNA1 (transfected with MYBBP1A-specific siRNA1). The immunoblot was performed against MYBBP1A, active Caspase 3 and Caspase 9;
tubulin is shown as loading control.
doi:10.1371/journal.pone.0039723.g005
MYBBP1A, Cell Cycle and Cancer
PLOS ONE | www.plosone.org 9 October 2012 | Volume 7 | Issue 10 | e39723
shown in Figure 7C, Mybbp1a down-regulated NIH-3T3 cells did
not induce tumor formation on their own. However, Ras-
transformed, Mybbp1a-down-regulated NIH-3T3 cells showed
significantly accelerated tumor formation in nude mice compared
to control Ras-transformed cells. The results therefore indicate
that Mybbp1a has a tumor-suppressive function.
Discussion
The present data define an essential role of MYBBP1A in cell
cycle and mitosis, as its absence/down-regulation causes chromo-
somal defects, G2/M arrest, mitotic anomalies and enhances the
tumorigenicity of Ras. We have examined the function of
MYBBP1A in vivo, in primary mouse cells (ES and MEFs), in
immortalized NIH3T3 and in cancer HeLa cells. In all cases, the
deletion or down-regulation of MYBBP1A has had a profound
effect on the growth rate of the cells.
In vivo, MYBBP1A deletion leads to embryonic death at the
blastocyst stage. Further analysis is required to determine what is
occurring in the mutant embryos and whether cell division defects,
as observed in the cell lines tested here, are responsible. Gene
expression analyses of human MYBBP1A down-regulated HeLa
cells shows altered expression of genes involved in chromosome
segregation, kinetochore formation and, in general, mitosis. The
involvement of MYBBP1A in mitosis is also directly suggested by
its peri-chromosomal localization during metaphase (Figure 6).
Indeed, MYBBP1A is phosphorylated by Aurora B at serine 1303
in nocodazole-arrested cells and is dephosphorylated upon Aurora
B silencing or by treatment with Danusertib, a small molecule
inhibitor of Aurora kinases [14]. It is therefore possible that
Figure 6. Mybbp1a localization during mitosis. Representative confocal images of NIH 3T3 cells stably expressing Mybbp1a-Flag in the cell-
cycle phases indicated on the left. (A) The staining was performed with anti-Flag (p160, green), anti-Phospho-Histone-H3 (PH3, red) and DAPI (blue)
for DNA. (B) Staining with anti-Flag (p160, red), anti-Nucleolin (green) and DAPI (blue) for DNA. (C) Staining with anti-Flag (p160, red), anti-
Nucleophosmin (NPM, green) and DAPI (blue) for DNA. Bar = 5 mm. The magnification is the same in all panels.
doi:10.1371/journal.pone.0039723.g006
Table 2. Genes differentially expressed in MYBBP1A-down-
regulated HeLa cells*.
N (%)
Total Number of detected genes on chip 28829
Total Number of differentially expressed genes1 853 (2.96%)
Up-regulated genes 244 (28.6%)
Down-regulated genes 609 (71.4%)
*Data obtained with a human Affymetrix ST 1.0 chip. Analysis of gene
expression profiling on HeLa cells transfected with siRNA3, harvested 48 h after
transfection.
1Genes whose expression level varied by more than 50% (p,0.0001).
doi:10.1371/journal.pone.0039723.t002
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MYBBP1A functions downstream of the Aurora B pathway,
possibly in kinetochore formation and or chromosome segregation.
Down-regulation of MYBBP1A in normal primary cells like ES
and MEFs has an effect superimposable to that on human cancer
HeLa cells, i.e. a strong decrease in growth rate and increased
apoptosis. In HeLa cells, surviving cells are blocked at the G2/M
stage of the cell cycle. The gene expression analysis highlights the
concordant mis-expression (increase of inhibitors, decrease of
activators) of genes important in cell cycle regulation. In addition,
this analysis revealed, as mentioned above, genes that are
important in chromosomal segregation and kinetochore forma-
tion. It appears therefore, that MYBBP1A affects two important
steps of cell division: the cell cycle and mitosis.
Mybbp1a down-regulation in NIH3T3 cells, however, has a
different effect - stimulating rather than blocking growth, and
enhancing Ha-RasV12 tumorigenesis. In these cells, the shRNA
constructs were somewhat less efficient, in general causing about
60% decrease in Mybbp1a levels (Fig. 2D). It is not clear whether
the different behavior of NIH3T3 cells is linked to this less
complete down-regulation or to the presence of mutations
accumulated during the long culture period in the laboratories.
NIH3T3 cells are clearly different from primary cells: for example,
they can be transformed by a single oncogene instead of two. This
is due to the presence of mutations which have led to
immortalization. Yet in this case, Mybbp1a down-regulation still
affects cell proliferation, although in the opposite direction. It will
be interesting to screen NIH3T3 cells for genes modifying
Mybbp1a function and to see which are affected by MYBBP1A
knock-down. The NIH3T3 transformation data also suggest that
Mybbp1a might be able to act as a tumor suppressor gene in some
contexts. Indeed, Mybbp1a possesses the important properties of
controlling cell cycle and tumorigenicity of the Ras oncogene. A
tumor-suppressor function is in line with all the results reported in
this paper. Interestingly, MYBBP1A maps to human chromosome
17p13.3 in a region that is frequently translocated in human
cancers (http://cgap.nci.nih.gov/Chromosomes/Mitelman).
In HeLa cells, a strong down-regulation of MYBBP1A affected
the expression of several genes involved in cell cycle control, DNA
damage and cell death (Table 4, Figure 8). In particular, genes
inhibiting growth were up-regulated while genes important in
DNA repair were down-regulated. These effects converge on the
regulation of the Cdc2-cyclinB kinase complex (Fig. 8) and hence
of the G2/M phase. In normal cells CDKN1A (p21) induces
senescence [27] while GADD45 induces G2/M block [8]. On the
other hand, BRCA1, the two topoisomerases TOP2a-TOP2b
which are essential in DNA repair, and Wee1 which stimulates the
G2/M phase were down-regulated. Since in HeLa cells p53 is
inactivated by HPV E6, the upregulation of CDKN1A suggests
that MYBBP1A prevents the transcriptional induction of
CDKN1A by a p53-independent mechanism.
The down-regulation of MYBBP1A induces also a variety of
mitotic anomalies which are not observed in control cells
(Figure 4 and Suppl. Figure S6). Analysis of the genes affected
Table 3. Gene Onthology Analysis of the differentially
expressed genes following MYBBP1A-down-regulation in HeLa
cells.
GO Term N. genes % p-value
Cell cycle 72 9.3 1.4E210
Mitosis 27 3.5 1.3E26
Cell cycle arrest 15 1.9 8.0E25
Chromosome segregation 17 2.2 1.5E27
Sister chromatid exchange 12 1.6 1.7E27
Chromosome condensation 16 2.1 2.0E24
Spindle 17 2.2 2.7E24
Response to DNA damage 37 4.8 1.8E26
Apoptosis 46 6.0 7.8E25
Microtubule organizing center 25 3.2 8.1E25
Centrosome 23 3.0 9.6E25
Chromatin 21 2.7 1.5E24
Cellular response to stress 52 6.7 1.1E27
N= total number of differentially expressed genes within the GO cathegory.
%: percent of the total number of differentially expressed genes.
p-value: calculated on the basis of the enrichment of the category (ie number of
genes affected/number of genes in the category).
doi:10.1371/journal.pone.0039723.t003
Table 4. Validation by Q-PCR of the gene expression profile
in MYBBP1A-depleted HeLa cells. #.
Gene Ratio*
CKS1 0.977+/20,085632938***
GADD45B 4.88+/20,886155931***
CDKN1A (P21) 10.45+/20,449326533***
SFN 1.29+/20,088121129
NFKB2 2.9+/20,0675**
cJUN 3.05+/20,246***
MYBBP1A 0.09+/20,00665***
TOP2A 0.27+/20,014977761***
TOP2B 0.21+/20,030892286***
WEE1 0.81+/20,144244006**
BRCA1 0.35+/20,029816103***
CDK7 0.76+/20,097858742**
#Real-Time PCR was performed on HeLa control (High-GC) or MYBBP1A-
depleted HeLa cells (siRNA1) with the same RNA samples used for microarray
experiment. Two biological replicates were used for each condition and the
experiment was performed in triplicate; an arbitrary value of 1 was given to the
control (CTL).
*Ratio between the expression in down-regulated vs. control (see Methods)
cells.
**p#0.01.
***p#0.001 (t test).
doi:10.1371/journal.pone.0039723.t004
Table 5. Tumorigenesis by RasVal12 in NIH3T3 cells infected
with an empty vector (C) or with a retrovirus carrying an
shRNA specific for MYBBP1A (Sh3).
N#
Tumor Volume#+/2SEM*
at day =18 p-value$
C 6 0
Sh3 6 0
C+RasV12 6 1.75+/20.22
Sh3+RasV12 6 2.43+/20.23 0.048
#Total number of mice in the group.
#volume expressed in cm3.
*SEM= Standard Error of the Mean.
$Student’s t-test.
doi:10.1371/journal.pone.0039723.t005
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by the MYBBP1A down-regulation (Table 3) shows alterations in
the expression of another very relevant set of genes directly
involved in mitosis, chromosome condensation, segregation, sister
chromatid exchange, formation of the spindle, microtubule
organizing center and centrosome. In fact, also some of the
validated genes (CDKN1A, TOP2A, TOP2B, GADD45A) have
been directly linked to mitosis.
In summary, our data indicate that MYBBP1A has at least two
important functions which are essential for embryo development
and cell proliferation: cell cycle and chromosome segregation
control. At the same time it is clear that other as yet undetermined
proteins mediate the function of MYBBP1A. Transformation
protein p53 might be one of them since MYBBP1A modulates p53
activity. However p53 is inactivated in HeLa cells, which allowed
us to investigate MYBBP1A in the absence of a functional p53.
Yet, the genes affected by MYBBP1A and p53 are partly
overlapping and thus it is possible that the pathways affected by
the two proteins intersect.
It is interesting to notice that loss of the MYBBP1A partner
Prep1 [4] has a similar phenotype. Prep1-null embryos die very
early in embryogenesis because they accumulate DNA damage; on
the other hand, heterozygous or hypomorphic mice develop
tumors [18,28,29]. Whether these two proteins also interact to
regulate the functions described above remains to be established.
Figure 7. Down-regulation of Mybbp1a in NIH3T3 cells favors transformation by RasV12. (A) Soft agar colony assay with NIH 3T3 cells
infected with non-target vector (NT), shRNA1 or shRNA3 lentiviruses with or without co-infection with pBABE-RasVal12 retrovirus. 50,000 cells were
plated in triplicate in soft agar and the images recorded 9 days after plating. The left panel shows examples of the actual plates, the right panel the
quantification of the experiment. (B) Immunoblot analysis of the levels of Ras and Mybbp1a after infection with pBABE-RavV12 and SH3 or NT (empty,
non target control) lentivirus, respectively. The apparent difference in the level of Ras in this blot is due to a difference in loading (see the actin band).
(C) Enhanced tumor growth rate upon Mybbp1a depletion. Cells were injected in the flank of nude mice (n = 6/group) and the size of the tumor
evaluated at different times thereafter (ordinates, days). NIH3T3 cells were infected with non-target empty lentivirus vector (NT) alone (#), non-
targeting lentivirus vector (NT) plus pBABE-RasV12 (N), Mybbp1a-specific shRNA3 lentivirus vector alone (%) or Mybbp1a-specific shRNA3 lentivirus
vector plus pBABE-RasV12 (&). At each time point, the Student’s t-test gave a p-value of 0.0188 (11 days), 0.0334 (13 days), 0.035 (15 days) and 0.048
(18 days). This panel shows a single experiment, representative of a total of three, with the same result.
doi:10.1371/journal.pone.0039723.g007
Figure 8. Connection between MYBBP1A, cell cycle genes and
their function. The figure depicts the connection between MYBBP1A,
the genes regulating the cell cycle that are altered by MYBBP1A down-
regulation and their function. In particular, the expression of red genes is
increased in the absence of MYBBP1A, while those in blue are decreased.
Thus, MYBBP1A induces the inhibitors of Cdc2/cyclinB and down-regulates
the activators. Note that although the figure focuses on the G2/M phase,
some of the genes function also at the G1/S (in particular CDKN1A).
MYBBP1A might act by regulating the synthesis and/or activity of one or
more of its partner transcription factors (cMyb, cJun, NF-kB). In fact, the
level of cJun mRNA is increased uponMYBBP1A down-regulation (Table 4).
doi:10.1371/journal.pone.0039723.g008
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Supporting Information
Figure S1 Targeted disruption of a Mybbp1a allele. (A)
Targeting strategy. The wild type Mybbp1a locus spanning the
coding region (18.2 kb) is depicted (top). The Mybbp1a targeting
vector (see Materials and Methods) was constructed using
Mybbp1a 59 genomic sequences (3.5 kb) and 39 sequences
(6.0 kb) flanking a pgkNEO expression cassette (1.8 kb) as shown.
The targeted allele maintains the 39 region, but removes 59 region
including the initiation codon (ATG) and exons 1–13, as depicted
(bottom). Non-coding sequences are shown as thick black lines,
exons are black boxes and restriction enzyme sites are indicated as
H, HindIII, and X, XbaI. (B) Genotyping of ES cells and mice.
XbaI digestion of genomic DNA produces a 7.4 kb fragment
detected by the 59 probe that corresponds to the wild type locus
and a 5.2 kb fragment that corresponds to the targeted locus. The
region between the dashed lines corresponds to the region of the
wild type locus that was replaced with the pgkNEO cassette in the
targeted allele. The location of the 59 and 39 probes is shown.
Restriction enzyme sites are indicated as H, HindIII and X, XbaI.
(C) Southern blot of XbaI-digested genomic DNA from wild type
(WT) and heterozygous Mybbp1a+/2 mice. The 59probe detects
the 7.4 kb upper band corresponding to the wild type Mybbp1a
allele and the 5.2 kb band corresponding to the targeted allele. (D)
PCR genotyping of mouse embryos from Mybbp1a+/2 intercross-
es. Controls are in lane 1 (2), which lacks template and contains
the 3 primers KO3, KO4 and KO5, and lanes 2 and 3 (C+/2),
which is genomic DNA from an adult heterozygous mouse. The
remaining lanes are material from blastocyst outgrowths harvested
from Mybbp1a+/2 intercrosses. The upper band of 570 bp
corresponds to the targeted allele and the 488 bp lower band
corresponds to the wild type allele. Each allele was detected in a
separate reaction. M, DNA size markers.
(TIF)
Figure S2 Mybbp1a redistribution at mitosis. A. Repre-
sentative immunofluorescence confocal images of NIH 3T3 cells
stably expressing Mybbp1a-Flag (p160-Flag) in the mitotic phases
indicated on the left. Cells were stained with antibodies against
Flag (Mybbp1a, red), a-Tubulin (green) and DAPI (blue) for DNA.
Bar = 10 mm. B. Immunofluorescence staining of endogenous
Mybbp1a in NIH3T3 cells compared with the staining of the cells
overexpressing Mybbp1a-Flag.
(PDF)
Figure S3 Mybbp1a does not localize at the kinetocore
and on telomeres. Representative confocal immunofluores-
cence of NIH 3T3 cells stably expressing Mybbp1a-Flag in the
cell-cycle phases indicated on the left of the panels. The staining
was performed against Flag (Mybbp1a, green), CREST (red, panel
A), PNA (red, panel B) and with DAPI (blue) for DNA.
Bar = 5 mm.
(TIF)
Figure S4 Immunofluorescence analysis of MYBBP1A
localization at interphase (top) and metaphase (bottom)
in HeLa cells. MYBBP1A localizes in the nucleoli at interphase
but around the chromosomes at metaphase.
(TIF)
Figure S5 Cell Cycle defects in MYBBP1A-depleted
HeLa cells. Four examples of time-lapse microscopic analysis,
showing the widespread variation of the time required for mitosis
after MYBBP1A-specific downregulation with si1 siRNA in HeLa
cells. MYBBP1A-silenced cells have an extended mitotic period.
Wide-field Time-Lapse video imaging of HeLa cells transfected
with siRNA1 for 48 hours and synchronized with double
thymidine block. Images were taken every 5 minutes starting
8 hours after the release from the block (mitosis start) with Oko-
Vision Time Lapse microscope for a total of 18 hours. Four
different examples are provided.
(TIF)
Figure S6 Representative mitotic alterations caused by
MYBBP1A depletion. Confocal microscopy of control (A) and
siRNA1 transfected (for 48 hrs) HeLa cells (B). In panel B: 1)
multipolar spindle, 2) and 3) altered metaphasic plate, 4) triangular
cytodieresis. Cells were stained with anti-Tubulin (green) antibod-
ies to image the mitotic spindle and with DAPI (blue) for DNA.
Bar = 12 mm.
(TIF)
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